A case of hypothyroidism and type 2 diabetes associated with type V hyperlipoproteinemia and eruptive xanthomas.
Primary hypothyroidism and type 2 diabetes are both typically associated with the increased level of triglycerides. To date, there have been only a few case reports of type 2 diabetes patients with both type V hyperlipoproteinemia and eruptive xanthomas, but there have been no reports of hypothyroidism patients associated with eruptive xanthomas. We report here on a case of a 48-yr old female patient who was diagnosed with type 2 diabetes and primary hypothyroidism associated with both type V hyperlipoproteinemia and eruptive xanthomas. We found rouleaux formation of RBCs in peripheral blood smear, elevated TSH, and low free T4 level, and dyslipidemia (total cholesterol 18.1 mM/L, triglyceride 61.64 mM/L, HDL 3.0 mM/L, and LDL 2.54 mM/L). She has taken fenofibrate, levothyroxine, and oral hypoglycemic agent for 4 months. After treatment, both TSH level and lipid concentration returned to normal range, and her yellowish skin nodules have also disappeared.
Park
Jeong Rang
JR
Department of Internal Medicine, College of Medicine, Gyeongsang National University, Jinju, Korea.
Jung
Tae Sik
TS
Jung
Jung Hwa
JH
Lee
Gyeong-Won
GW
Kim
Me Ae
MA
Park
Ki-Jong
KJ
Kim
Deok Ryong
DR
Chang
Se-Ho
SH
Chung
Soon Il
SI
Hahm
Jong Ryeal
JR
D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D004903:Erythrocyte Aggregation; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood; D006954:Hyperlipoproteinemia Type V / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007037:Hypothyroidism / Q000097:blood / Q000150:complications* / Q000188:drug therapy; D008875:Middle Aged; D012871:Skin Diseases / Q000097:blood / Q000150:complications / Q000188:drug therapy; D013972:Thyrotropin / Q000097:blood / Q000627:therapeutic use; D013974:Thyroxine / Q000097:blood; D016896:Treatment Outcome; D014973:Xanthomatosis / Q000097:blood / Q000150:complications* / Q000188:drug therapy
D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D013972:Thyrotropin; D013974:Thyroxine; D011345:Fenofibrate